“The new virus originating from Wuhan is the third coronavirus that has made the ‘jump’ from animals to humans,” explains Enrico Bucci, Ph.D., professor and research scientist at the Sbarro Health Research Organization (SHRO), at Temple University in Philadelphia.
Immunotherapy using LEAPS peptide technology may be able to reduce COVID-19 viral load and tissue damage resulting from infection in the lungs.
A protein produced by the human immune system can potently inhibit several coronaviruses, including the one behind the current COVID-19 outbreak.
The world is bracing for the impact of the novel coronavirus, COVID-19, which has now spread to over 30 countries, infecting more than 80,000 people with over 2,600 deaths globally.
The world is bracing for the impact of the novel coronavirus, COVID-19, which has now spread to over 30 countries, infecting more than 80,000 people with over 2,600 deaths globally.
n article by radiologists from Wuhan, China--published open-access and ahead-of-print in the American Journal of Roentgenology (AJR)--concluded that chest CT had a low rate of misdiagnosis of COVID-19 (3.9%, 2/51) and could help standardize imaging features and rules of transformation for rapid diagnosis; however, CT remains limited for the identification of specific viruses and distinguishing between viruses.
With seven reported cases in Florida to-date, FAU emergency medicine resident physicians prepared for the threat of a coronavirus contagion using a simulated or “mock” disaster scenario at FORTS Medical. The simulation involved a cruise ship dock-setting scenario and mock passengers were transported by bus. The passengers stormed into the large warehouse to challenge the resident physicians to react and respond quickly to triage the patients. About 100 people participated in the half-day simulation including local nurses, paramedics, and student and community actors.
On March 5, U.S. House and Senate lawmakers introduced the VALID Act, which would give the Food and Drug Administration (FDA) new, expansive powers to regulate laboratory developed tests—tests that are already regulated by the Centers for Medicare and Medicaid Services (CMS) and are subject to stringent personnel, quality control, and proficiency testing requirements. This bill promotes duplicative, costly federal regulations for clinical laboratories that will result in decreased patient access to essential medical tests. AACC urges Congress not to act on this bill until its impact on healthcare can be thoroughly evaluated.
A University of Washington researcher calculates that 14.4 million workers face exposure to infection once a week and 26.7 million at least once a month in the workplace, pointing to an important population needing protection as the novel coronavirus disease, COVID-19, continues to break out across the U.S.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
